Full-Time
Confirmed live in the last 24 hours
Develops microbiome-based therapies for diseases
No salary listed
Senior, Expert
Milpitas, CA, USA
Seres Therapeutics develops microbiome-based therapies that use beneficial bacteria to treat diseases, particularly focusing on conditions like Clostridium difficile infection (CDI) and other gastrointestinal disorders. Their approach aims to restore the natural balance of bacteria in the human body, addressing the root causes of these diseases. Unlike many traditional treatments that may only alleviate symptoms, Seres targets the underlying issues through its innovative therapies. The company collaborates with healthcare providers and research institutions to enhance its solutions and operates in the biopharmaceutical market, which is known for its growth potential. Seres generates revenue from the sale of its approved therapies and licensing agreements, while heavily investing in research and development to bring new treatments to market. The goal of Seres Therapeutics is to transform patient lives by providing effective microbiome-based treatments that meet unmet medical needs.
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Lisa von Moltke will resign from Seres Therapeutics in March 2025.
CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. MCRB (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company's previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. As previously announced, based on the Company's existing cash, inclusive of this payment, a projected installment payment from Nestlé Health Science in July 2025 of $25 million (less up to approximately $1.5M in employment-related payments to Nestlé Health Science), transaction-related obligations and current operating plans, the Company expects to fund operations into the first quarter of 2026. About Seres Therapeutics Seres Therapeutics, Inc. MCRB is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics
Hensley joins from Seres Therapeutics, where she served as senior vice president, assistant general counsel and chief compliance officer, overseeing corporate legal and compliance matters.
Seres Therapeutics secures $175M in Nestlé deal.
CAMBRIDGE, Mass., June 12, 2024 - Flagship Pioneering and ProFound(TM) Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, today announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity.